CEL-SCI Corporation
CVMCEL-SCI Corporation in brief
CEL-SCI Corporation is a listed company in the Biotechnology industry, based in Vienna, Virginia, USA. It was founded in 1983. Its market value was $26 M on 30 October 2026, which makes it the 23,462nd largest listed company in the world and the 4,073rd largest in the USA on this site. Geert R. Kersten is its chief executive. Its shares trade under the symbol CVM (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About CEL-SCI Corporation
Cel-Sci Corporation (NYSE American: CVM), is a biotechnology company that tests drugs for the treatment of cancer, autoimmune and infectious diseases through the research and development of immunotherapy products.
Cel-Sci's main product is the drug Multikine, an immunotherapeutic agent designed to fight cancer by stimulating the body's immune system. Multikine is currently in Phase III of Clinical Trials with the Food and Drug Administration (FDA). Multikine has also been referred to as Leukocyte Interleukin Injection (LI). Multikine was in Phase II testing of patients with head and neck cancer in the early 2000s, in which it demonstrated tumor-reducing ability. In January 2007, the US cleared the Phase 3 trial and Multikine was designated as an orphan drug by the FDA for neoadjuvant therapy of patients with squamous cell carcinoma of the head and neck. A total of 928 patients were enrolled in the head and neck cancer drug trial at that time. Subsequently, in June 2021, the company announced that the study missed its primary endpoint.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
CEL-SCI Corporation timeline
- 1983
- 🏁· approximateIncorporated as CEL-SCI Corporation
- 1996
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 1997
- 🔔· approximateInitial public offering on Nasdaq
- 2013
- •Legal Entity Identifier issuedLEI 549300FIWOFSETIVMI17 registered.
Events of CEL-SCI Corporation from the GLEIF LEI register, SEC EDGAR and the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,847 (Jan 2020) · #2,819 (Jan 2021) · #3,579 (Jan 2022) · #4,291 (Dec 2022) · #4,384 (Jul 2023) · #3,519 (Jan 2024) · #2,235 (Mar 2026) · #3,887 (Aug 2026) · #3,947 (Oct 2026) · #4,076 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 1.7×
- Free cash flow yield
- -65.0%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -159.2%
- Liabilities / assets
- 43.3%
- Revenue growth
- +62.5%
- R&D / revenue
- 5873.1%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Sep 2025 | — | — | $-25M | $-25M | — |
| Sep 2024 | — | — | $-26M | $-27M | — |
| Sep 2023 | — | — | $-31M | $-32M | — |
| Sep 2022 | — | — | $-36M | $-37M | — |
| Sep 2021 | — | — | $-36M | $-36M | — |
| Sep 2020 | — | — | $-29M | $-30M | — |
| Sep 2019 | — | — | $-20M | $-22M | — |
| Sep 2018 | — | — | $-17M | $-32M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Sep 2025 | $-17M | $0M | $-17M | $-6.27 | — |
| Sep 2024 | $-19M | $0M | $-19M | $-15.31 | — |
| Sep 2023 | $-23M | $0M | $-23M | $-0.73 | — |
| Sep 2022 | $-18M | $1M | $-19M | $-0.87 | — |
| Sep 2021 | $-19M | $9M | $-28M | $-0.90 | — |
| Sep 2020 | $-15M | $3M | $-18M | $-0.82 | — |
| Sep 2019 | $-16M | $-0M | $-16M | $-0.71 | — |
| Sep 2018 | $-13M | $0M | $-13M | $-1.87 | — |
Quarterly results
Latest quarter to Jun 2026: revenue —, net income $-6M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Aug 17, 20268-KCurrent reportShareholder vote
- Aug 14, 202610-QQuarterly report · period to Jun 2026
- Jul 2, 2026DEF 14AProxy statement
- Jun 16, 20268-KCurrent reportMaterial agreement · Other events
- May 15, 202610-QQuarterly report · period to Mar 2026
- May 14, 20268-KCurrent reportMaterial agreement
- May 13, 20268-KCurrent reportMaterial agreement · Other events
- May 13, 2026424B4IPO prospectus
- May 1, 2026S-1/AIPO registration (amended)
- Apr 17, 2026S-1IPO registration
- Feb 17, 202610-QQuarterly report · period to Dec 2025
- Dec 29, 202510-KAnnual report · period to Sep 2025
Official filings of CEL-SCI Corporation with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-25 M
- Net income
- $-25 M
For year ending September-2025 · source: SEC filing
Balance sheet
- Total assets
- $28 M
- Total liabilities
- $12 M
- Total equity
- $16 M
As of September-2025
Top 44 institutional investors in CEL-SCI Corporation#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 566,328 | +23,249 (+4.28%) | 3.22% | $1 M | Nov 13, 2026 |
| 2 | Renaissance Technologies LLC | 470,869 | -101,591 (-17.75%) | 2.68% | $1 M | Nov 12, 2026 |
| 3 | Citadel Advisors LLC | 162,140 | -36,360 (-18.32%) | 0.92% | $0 M | Nov 16, 2026 |
| 4 | Geode Capital Management, LLC | 130,171 | +41,971 (+47.59%) | 0.74% | $0 M | Nov 6, 2026 |
| 5 | MAI Capital Management | 109,280 | +1,000 (+0.92%) | 0.62% | $0 M | Nov 12, 2026 |
| 6 | Vanguard Fiduciary Trust Co | 102,757 | +53,721 (+109.55%) | 0.58% | $0 M | Nov 13, 2026 |
| 7 | Commonwealth Equity Services, LLC | 55,412 | +3,978 (+7.73%) | 0.32% | $0 M | Nov 2, 2026 |
| 8 | Jane Street Group, LLC | 44,845 | +8,387 (+23.00%) | 0.26% | $0 M | Nov 12, 2026 |
| 9 | Osaic Holdings, Inc. | 44,286 | +11,506 (+35.10%) | 0.25% | $0 M | Nov 12, 2026 |
| 10 | XTX Topco Ltd | 44,020 | +9,132 (+26.18%) | 0.25% | $0 M | Nov 16, 2026 |
| 11 | BlackRock, Inc. | 43,210 | -51 (-0.12%) | 0.25% | $0 M | Nov 13, 2026 |
| 12 | Bank Of America Corp /de/ | 40,989 | +73 (+0.18%) | 0.23% | $0 M | Nov 16, 2026 |
| 13 | US Bancorp \de\ | 29,907 | 0 (0.00%) | 0.17% | $0 M | Nov 5, 2026 |
| 14 | State Street Corp | 27,270 | 0 (0.00%) | 0.15% | $0 M | Nov 12, 2026 |
| 15 | Raymond James Financial Inc | 26,013 | +10,000 (+62.45%) | 0.15% | $0 M | Nov 12, 2026 |
| 16 | Northern Trust Corp | 21,141 | +58 (+0.28%) | 0.12% | $0 M | Nov 16, 2026 |
| 17 | Gsa Capital Partners LLP | 15,309 | New | 0.09% | $0 M | Nov 16, 2026 |
| 18 | WCG Wealth Advisors LLC | 12,260 | New | 0.07% | $0 M | Nov 16, 2026 |
| 19 | HighTower Advisors, LLC | 10,000 | 0 (0.00%) | 0.06% | $0 M | Nov 10, 2026 |
| 20 | Financial Consulate, Inc | 10,000 | 0 (0.00%) | 0.06% | $0 M | Oct 23, 2026 |
| 21 | Chilton Capital Management LLC | 9,156 | 0 (0.00%) | 0.05% | $0 M | Oct 28, 2026 |
| 22 | UBS Group AG | 8,520 | +495 (+6.17%) | 0.05% | $0 M | Nov 10, 2026 |
| 23 | Morgan Stanley | 3,041 | +3,000 (+7317.07%) | 0.02% | $0 M | Nov 13, 2026 |
| 24 | Tower Research Capital LLC (TRC) | 1,778 | New | 0.01% | $0 M | Nov 16, 2026 |
| 25 | Steward Partners Investment Advisory, LLC | 686 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
Show all 44: investors 26 to 44
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Vanguard Global Advisers, LLC | 536 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 27 | Hilton Head Capital Partners, LLC | 450 | 0 (0.00%) | 0.00% | $0 M | Oct 23, 2026 |
| 28 | Buck Wealth Strategies, LLC | 256 | 0 (0.00%) | 0.00% | $0 M | Oct 28, 2026 |
| 29 | Latitude Advisors, LLC | 205 | New | 0.00% | $0 M | Oct 27, 2026 |
| 30 | Jpmorgan Chase & Co | 153 | +146 (+2085.71%) | 0.00% | $0 M | Nov 12, 2026 |
| 31 | Royal Bank Of Canada | 145 | +83 (+133.87%) | 0.00% | $0 M | Nov 16, 2026 |
| 32 | Jones Financial Companies Lllp | 66 | New | 0.00% | $0 M | Nov 13, 2026 |
| 33 | BNP Paribas Financial Markets | 41 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 34 | Alerus Financial NA | 38 | 0 (0.00%) | 0.00% | $0 M | Nov 9, 2026 |
| 35 | Gables Capital Management Inc. | 26 | 0 (0.00%) | 0.00% | $0 M | Nov 4, 2026 |
| 36 | Huntington National Bank | 16 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
| 37 | Community Bank, N.A. | 16 | 0 (0.00%) | 0.00% | $0 M | Nov 6, 2026 |
| 38 | Allworth Financial LP | 4 | 0 (0.00%) | 0.00% | $0 M | Nov 17, 2026 |
| 39 | Golden State Wealth Management, LLC | 3 | 0 (0.00%) | 0.00% | $0 M | Nov 2, 2026 |
| 40 | Physician Wealth Advisors, Inc. | 3 | 0 (0.00%) | 0.00% | $0 M | Oct 20, 2026 |
| 41 | Caitong International Asset Management Co., Ltd | 3 | -2 (-40.00%) | 0.00% | $0 M | Oct 29, 2026 |
| 42 | Tounjian Advisory Partners, LLC | 2 | 0 (0.00%) | 0.00% | $0 M | Nov 4, 2026 |
| 43 | Mark Sheptoff Financial Planning, LLC | 1 | New | 0.00% | $0 M | Nov 16, 2026 |
| 44 | Jacobi Capital Management LLC | 1 | New | 0.00% | $0 M | Nov 5, 2026 |
Mutual funds holding CEL-SCI Corporation#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 456,941 | $0 M | 2.6% | <0.01% | +191% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 86,138 | $0 M | 0.49% | <0.01% | +8.5% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 42,461 | $0 M | 0.24% | <0.01% | −0.8% | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 12,164 | $0 M | 0.07% | <0.01% | +10.0% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 11,520 | $0 M | 0.07% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 7,500 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 45 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 7 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at CEL-SCI Corporation#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Geert R. KerstenChief Executive Officer, Director | Grant or award | +2,621 | $2.060 | $5 K | 318,763 | Form 4 |
| filed | Patricia B. PrichepChief Financial Officer | Grant or award | +2,082 | $2.060 | $4 K | 19,571 | Form 4 |
| filed | Eyal TalorChief Scientific Officer | Grant or award | +1,165 | $2.060 | $2 K | 10,483 | Form 4 |
| filed | Geert R. KerstenChief Executive Officer, Director | Buy | +100,000 | $1.380 | $138 K | 316,142 | Form 4 |
| filed | Patricia B. PrichepChief Financial Officer | Grant or award | +4,125 | $1.040 | $4 K | 17,489 | Form 4 |
| filed | Eyal TalorChief Scientific Officer | Grant or award | +2,307 | $1.040 | $2 K | 9,318 | Form 4 |
| filed | Geert R. KerstenChief Executive Officer, Director | Grant or award | +5,192 | $1.040 | $5 K | 216,142 | Form 4 |
| filed | Geert R. KerstenChief Executive Officer, Director | Buyindirect | +300,000 | $1.200 | $360 K | 311,547 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: CEL-SCI Corporation#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2025-07-28 13:37 UTC, code M, resumed 13:47 UTC
- 2025-07-11 15:57 UTC, code T3, resumed 16:55 UTC
- 2025-07-11 15:16 UTC, code M, resumed 15:26 UTC
- 2025-07-11 13:46 UTC, code M, resumed 13:56 UTC
- 2025-07-11 13:41 UTC, code M, resumed 13:46 UTC
Fails to deliver
- : 1,730 shares at $1.50
- : 1,146 shares at $1.64
- : 1 shares at $1.62
- : 580 shares at $2.13
- : 62 shares at $2.06
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
CEL-SCI Corporation scorecard#
Passes 3 of the 13 checks that could be worked out: strongest in financial health (1 of 3), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation1 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median1.6×Price to book 1.6× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-65.0%Free cash flow is -65.0% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-6.27 vs -15.31Diluted EPS -6.27 in fiscal 2025 against -15.31 the year before (report's currency).
- ✓Net income higher than five years earlier-$25 M-$25 M in fiscal 2025 against -$30 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$25 MNet income -$25 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-176.3%-176.3% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities2.3×Current ratio 2.26 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times-38.2×Operating income -38.2 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year125.1%Diluted shares up 125.1% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
CEL-SCI Corporation: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Sep 30, 2025 | FY 2024to Sep 30, 2024 | FY 2023to Sep 30, 2023 | FY 2022to Sep 30, 2022 | FY 2021to Sep 30, 2021 | FY 2020to Sep 30, 2020 | FY 2019to Sep 30, 2019 | FY 2018to Sep 30, 2018 | FY 2017to Sep 30, 2017 | FY 2016to Sep 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Research and development | 16−12.5%— | 18−19.2%— | 22−11.4%— | 25+9.7%— | 23+29.5%— | 18+40.9%— | 13+16.0%— | 11r9.4−30.1%— | 16−10.5%— | 17r19—— | |
| General and administrative | 8.9+8.9%— | 8.2−9.0%— | 9.0−15.9%— | 11−18.2%— | 13+11.8%— | 12+46.3%— | 8.0+26.3%— | 6.3r7.8+9.2%— | 5.8−10.6%— | 6.5—— | |
| Operating expenses | 25−5.9%— | 26−16.3%— | 31−12.7%— | 36−0.4%— | 36+22.5%— | 30+43.0%— | 21+19.8%— | 17−19.4%— | 21−10.5%— | 24r26—— | |
| Operating income | −25—— | −26—— | −31—— | −36—— | −36—— | −29—— | −20—— | −17—— | −21r−21—— | −24r−26—— | |
| Interest expense and finance costs | 0.6−13.0%— | 0.7r0.7+10.5%— | 0.7−37.5%— | 1.1—— | — | 1.2—— | — | — | — | — | |
| Net interest income | −0.6—— | −0.7—— | — | −1.1—— | −1.1—— | −1.0—— | −1.8—— | — | — | −1.9—— | |
| Other non-operating income (expense) | 0.0−73.2%— | 0.2—— | −0.0−140%— | 0.1—— | −0.0−121%— | 0.0—— | — | — | — | −1.9r0.1—— | |
| Income before tax | — | — | — | — | — | −30—— | −22—— | — | — | — | |
| Net income including minority interests | 25−5.6%— | 27r−27—— | −32—— | −37r37−201%— | 36—— | — | — | — | — | — | |
| Net income attributable to shareholders | −25—— | −27r−28—— | −32r−32—— | −37—— | −36—— | −30—— | −22—— | −32—— | −14—— | −12r−11—— | |
| Earnings per share, basic | — | — | — | -0.87—— | -0.90—— | -0.82—— | -0.71—— | -1.87—— | -1.83—— | -2.37r-0.09—— | |
| Earnings per share, diluted | -6.27—— | -15.31r-0.51—— | -0.73—— | -0.87—— | -0.90r-0.93—— | -0.82—— | -0.71—— | -1.87—— | -1.91—— | -2.37r-0.09—— | |
| Shares, weighted average (basic) | — | — | — | 43+6.1%— | 41+10.6%— | 37+17.9%— | 31+83.3%— | 17+115%— | 7.9+62.2%— | 4.9r122—— | |
| Shares, weighted average (diluted) | 4.1+125%— | 1.8r54−95.9%— | 44+3.1%— | 43+6.0%— | 41+10.7%— | 37+17.9%— | 31+83.3%— | 17+115%— | 7.9+62.4%— | 4.9r122—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 11+131%38.9% | 4.7+14.3%17.6% | 4.1−81.7%13.6% | 23−37.1%44.9% | 36+133%47.5% | 16+83.7%38.3% | 8.4−18.1%30.6% | 10+335%34.8% | 2.4−18.8%10.3% | 2.9—11.7% | |
| Short-term investments | — | — | — | 0−100%0.0% | 6.2—8.1% | 0—0.0% | — | — | — | — | |
| Receivables | — | — | — | 0−100%0.0% | 0.10.0%0.1% | 0.1−12.5%0.1% | 0.1−47.1%0.2% | 0.1−45.7%0.4% | 0.2−44.6%1.0% | 0.4—1.6% | |
| Inventory | — | 1.0−54.6%3.8% | 2.2+12.3%7.4% | 2.0−0.2%4.0% | 2.0+145%2.6% | 0.8+4.8%2.0% | 0.8+21.3%2.8% | 0.6−4.1%2.2% | 0.7−33.3%2.9% | 1.0—4.1% | |
| Current assets | 12+91.5%41.2% | 6.1−12.5%22.4% | 6.9−72.8%22.7% | 25−43.8%50.3% | 45+156%59.7% | 18+80.3%43.7% | 9.8−14.2%35.5% | 11+170%38.7% | 4.2−22.4%18.5% | 5.5r5.9—21.9% | |
| Property, plant and equipment | 6.1−25.2%21.6% | 8.1−20.2%30.1% | 10−14.3%33.4% | 12−13.0%23.5% | 14+134%18.0% | 5.8−63.1%14.4% | 16−2.4%57.3% | 16−3.4%54.8% | 17−3.2%73.3% | 17r0.2—69.7% | |
| Right-of-use (leased) assets | 1.3−14.8%4.5% | 1.5−11.9%5.5% | 1.7−9.9%5.6% | 1.9−8.4%3.7% | 2.1+71.5%2.7% | 1.2—3.0% | 0—0.0% | — | — | — | |
| Other intangible assets | 0.1−27.6%0.4% | 0.2−16.3%0.6% | 0.2−6.8%0.6% | 0.2−23.1%0.4% | 0.3—0.4% | — | 0.3+20.7%1.1% | 0.3+15.7%0.9% | 0.2−13.0%1.0% | 0.3—1.0% | |
| Non-current assets | — | — | — | — | — | 1.70.0%4.2% | 1.7r0.0—6.2% | — | — | — | |
| Total assets | 28+4.3%100% | 27−11.6%100% | 31−39.6%100% | 51−33.4%100% | 76+87.2%100% | 41+46.7%100% | 28−6.6%100% | 30+29.1%100% | 23−7.9%100% | 25r12—100% | |
| Accounts payable | 1.1−26.7%3.8% | 1.4−27.9%5.4% | 2.0+24.2%6.6% | 1.6−3.4%3.2% | 1.7−17.2%2.2% | 2.0+27.5%5.0% | 1.6−72.4%5.7% | 5.7−29.9%19.4% | 8.2+165%35.8% | 3.1—12.4% | |
| Customer deposits | — | — | — | — | — | — | — | — | — | 0.0—0.0% | |
| Debt due within a year | 2.3—8.1% | — | — | — | — | — | — | — | — | — | |
| Current liabilities | 5.1+11.2%18.2% | 4.6−17.4%17.1% | 5.6+19.8%18.3% | 4.7+18.5%9.2% | 3.9−7.7%5.2% | 4.3+41.3%10.5% | 3.0−67.3%10.9% | 9.2−14.9%31.2% | 11+170%47.3% | 4.0—16.1% | |
| Long-term debt | 5.7—20.2% | — | — | — | — | — | — | — | — | — | |
| Lease liabilities (non-current) | 1.3−11.7%4.5% | 1.4−13.7%5.3% | 1.7−10.7%5.4% | 1.9−8.5%3.7% | 2.0+81.4%2.7% | 1.1—2.7% | 0—0.0% | — | — | — | |
| Total liabilities | 12−13.6%43.3% | 14−18.4%52.3% | 17−5.7%56.7% | 18−5.0%36.3% | 19−7.1%25.5% | 21−7.5%51.3% | 22−24.0%81.4% | 30+12.7%100.0% | 26+2.7%115% | 26r13—103% | |
| Retained earnings | −539—−1916% | −514—−1904% | −487—−1596% | −455—−900% | −418—−551% | −382—−942% | −354—−1281% | −332—−1121% | −300—−1308% | −285r−286—−1147% | |
| Shareholders' equity | 16+24.0%56.7% | 13−2.6%47.7% | 13−58.9%43.3% | 32−43.1%63.7% | 57+187%74.5% | 20+284%48.7% | 5.1+560344%18.6% | 0.0—0.0% | −3.3—−14.6% | −0.7r−1.0—−2.7% | |
| Total equity | — | — | — | — | — | — | — | — | — | −0.7—−2.7% | |
| Total liabilities and equity | 28+4.3%100% | 27−11.6%100% | 31−39.6%100% | 51−33.4%100% | 76+87.2%100% | 41+46.7%100% | 28−6.6%100% | 30+29.1%100% | 23−7.9%100% | 25r12—100% | |
| Shares outstanding | 8.0+277%— | 2.1r64−95.5%— | 47+9.1%— | 43+0.6%— | 43+11.6%— | 39+9.9%— | 35+25.7%— | 28+136%— | 12+90.5%— | 6.2r156—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 2.1−3.7%— | 2.1+1.0%— | 2.1+6.9%— | 2.0+342%— | 0.4+14.9%— | 0.4r2.1−33.8%— | 0.6+2.3%— | 0.6−3.0%— | 0.6−5.3%— | 0.6r0.1—— | |
| Share-based compensation | 1.9−55.2%— | 4.3−32.1%— | 6.3−44.8%— | 11−16.8%— | 14+35.3%— | 10+128%— | 4.4+61.4%— | 2.7+98.7%— | 1.4−34.7%— | 2.1—— | |
| Cash from operating activities | −17—— | −19—— | −23—— | −18—— | −19—— | −15—— | −16—— | −13—— | −14—— | −23—— | |
| Capital expenditure | −0.0—— | −0.1—— | −0.4—— | −0.6—— | −9.0—— | −2.7r−2.7—— | −0.2r−0.2—— | −0.0—— | −0.0—— | −0.0—— | |
| Intangible assets bought | 0—— | −0.0—— | −0.0—— | −0.0—— | −0.0—— | −0.0r−0.0—— | −0.2r−0.2—— | −0.1—— | −0.0—— | −0.0—— | |
| Cash from investing activities | −0.0—— | −0.1—— | −0.4−107%— | 5.5—— | −15—— | −2.7—— | −0.3—— | −0.1—— | −0.0—— | −0.0—— | |
| Shares issued | 28+20.0%— | 24+260%— | 6.6—— | — | 47+238%— | 14—— | 0−100%— | 12r12+12.1%— | 11−50.9%— | 21—— | |
| Cash from financing activities | 23+19.8%— | 20+316%— | 4.7—— | −0.6−101%— | 55+118%— | 25+69.3%— | 15−30.8%— | 21+61.3%— | 13−34.7%— | 20—— | |
| Change in cash | — | — | — | — | 21+191%— | 7.1—— | −1.9−123%— | 7.9—— | −0.5—— | −2.8—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K/A | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jun 30, 2026 | Q3 FY2026to Jun 30, 2026 | Q2 FY2026to Mar 31, 2026 | Q1 FY2026to Dec 31, 2025 | Q4 FY2025to Sep 30, 2025 | Q3 FY2025to Jun 30, 2025 | Q2 FY2025to Mar 31, 2025 | Q1 FY2025to Dec 31, 2024 | Q4 FY2024to Sep 30, 2024 | Q3 FY2024to Jun 30, 2024 | Q2 FY2024to Mar 31, 2024 | Q1 FY2024to Dec 31, 2023 | Q4 FY2023to Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 15−11.2%— | 3.6−2.4%— | 3.8−6.2%— | 3.7−17.0%— | 3.7*−17.3%— | 3.7−20.5%— | 4.0−13.3%— | 4.4+1.8%— | 4.5*−15.0%— | 4.7—— | 4.6—— | 4.4—— | 5.3*—— | |
| General and administrative | 7.5−9.1%— | 1.9+9.1%— | 1.6−34.5%— | 1.7−31.3%— | 2.3*+41.8%— | 1.7−11.1%— | 2.4−2.8%— | 2.5+15.5%— | 1.6*−25.3%— | 2.0—— | 2.4—— | 2.1—— | 2.2*—— | |
| Operating expenses | 22−10.5%— | 5.6+1.2%— | 5.3−16.7%— | 5.4−22.1%— | 6.0*−1.4%— | 5.5−17.7%— | 6.4−9.6%— | 6.9+6.3%— | 6.1*−18.0%— | 6.7—— | 7.1—— | 6.5—— | 7.5*—— | |
| Operating income | −22—— | −5.6—— | −5.3—— | −5.4—— | −6.0*—— | −5.5—— | −6.4—— | −6.9—— | −6.1*—— | −6.7—— | −7.1—— | −6.5—— | −7.5*—— | |
| Interest expense and finance costs | 0.4—— | 0.1−35.5%— | 0.1−34.3%— | 0.1−48.2%— | 0.1*—— | 0.2—— | 0.2—— | 0.2—— | — | — | — | — | — | |
| Net interest income | −0.4—— | −0.1—— | −0.1—— | −0.1—— | −0.1*—— | −0.2—— | −0.2—— | −0.2—— | −0.2*—— | −0.2—— | −0.2r0.2—— | −0.2—— | — | |
| Other non-operating income (expense) | 0.0−85.0%— | 0—— | −0.0—— | −0.0—— | 0.1*−67.1%— | −0.0−186%— | 0—— | −0.0—— | 0.2*—— | 0.0—— | — | — | — | |
| Net income including minority interests | 23−66.1%— | 5.7+0.1%— | 5.5−16.8%— | 5.5−22.7%— | 6.1r45*−87.2%— | 5.7—— | 6.6—— | 7.1r−7.1—— | 48r−48*—— | −6.9r35*—— | −7.2*—— | −6.7—— | −57*—— | |
| Net income attributable to shareholders | −23—— | −5.7—— | −5.5—— | −5.5—— | −6.1*—— | −5.7—— | −6.6—— | −7.1—— | −6.1r−6.8*—— | −6.9—— | −7.2—— | −6.7—— | −7.8r−7.6*—— | |
| Earnings per share, diluted | — | -0.47—— | -0.67—— | -0.68—— | — | -1.36—— | -2.33r-0.08—— | -3.25r-0.11—— | — | -4.18—— | -0.14—— | -0.14—— | — | |
| Shares, weighted average (diluted) | 12+192%— | 12+192%— | 8.1+189%— | 8.0+268%— | — | 4.2+131%— | 2.8r85−94.6%— | 2.2r65−95.5%— | — | 1.8—— | 52—— | 48—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 6.5—30.6% | 6.5+264%30.6% | 1.9−1.7%10.7% | 6.3+36.1%27.4% | 11+131%38.9% | 1.8+366%8.8% | 1.9−63.8%8.8% | 4.6+42.3%18.0% | 4.7+14.3%17.6% | 0.4—1.6% | 5.3—17.7% | 3.2—11.3% | 4.1—13.6% | |
| Inventory | — | — | — | — | — | — | — | — | 1.0−54.6%3.8% | — | — | 2.3—8.2% | 2.2—7.4% | |
| Current assets | 7.5—35.1% | 7.5+186%35.1% | 2.9−4.3%16.3% | 7.0+20.0%30.7% | 12+91.5%41.2% | 2.6−26.0%12.9% | 3.0−64.5%13.9% | 5.9−4.8%22.8% | 6.1−12.5%22.4% | 3.5—14.7% | 8.5—28.3% | 6.2—21.4% | 6.9—22.7% | |
| Property, plant and equipment | 4.6—21.4% | 4.6−30.4%21.4% | 5.1−28.4%28.6% | 5.6−26.6%24.3% | 6.1−25.2%21.6% | 6.6−23.6%32.3% | 7.1−22.3%32.5% | 7.6−21.3%29.5% | 8.1−20.2%30.1% | 8.6—35.8% | 9.1—30.3% | 9.6—33.6% | 10—33.4% | |
| Right-of-use (leased) assets | 1.4—6.8% | 1.4+8.3%6.8% | 1.5+7.4%8.4% | 1.5+6.7%6.7% | 1.3−14.8%4.5% | 1.3−13.9%6.6% | 1.4−13.2%6.4% | 1.4−12.5%5.6% | 1.5−11.9%5.5% | 1.5—6.4% | 1.6—5.3% | 1.6—5.7% | 1.7—5.6% | |
| Other intangible assets | 0.1—0.3% | 0.1−46.6%0.3% | 0.1−48.1%0.4% | 0.1−31.6%0.4% | 0.1−27.6%0.4% | 0.1−24.5%0.6% | 0.1−21.7%0.6% | 0.1−21.2%0.6% | 0.2−16.3%0.6% | 0.2—0.7% | 0.2—0.6% | 0.2—0.7% | 0.2—0.6% | |
| Total assets | 21—100% | 21+5.0%100% | 18−18.8%100% | 23−10.9%100% | 28+4.3%100% | 20−15.5%100% | 22−27.4%100% | 26−10.5%100% | 27−11.6%100% | 24—100% | 30—100% | 29—100% | 31—100% | |
| Accounts payable | 1.0—4.8% | 1.0−35.1%4.8% | 0.9−45.1%5.3% | 1.0−48.2%4.5% | 1.1−26.7%3.8% | 1.6+15.2%7.8% | 1.7+67.5%7.8% | 2.0+74.7%7.8% | 1.4−27.9%5.4% | 1.4—5.7% | 1.0—3.4% | 1.1—4.0% | 2.0—6.6% | |
| Debt due within a year | — | — | — | — | 2.3—8.1% | — | — | — | — | — | — | — | — | |
| Current liabilities | 5.1—23.8% | 5.1−9.6%23.8% | 4.8−12.6%27.2% | 5.0−8.0%22.0% | 5.1+11.2%18.2% | 5.6+2.0%27.6% | 5.5+8.1%25.2% | 5.5+12.6%21.3% | 4.6−17.4%17.1% | 5.5—22.9% | 5.1—16.9% | 4.9—17.0% | 5.6—18.3% | |
| Long-term debt | — | — | — | — | 5.7—20.2% | — | — | — | — | — | — | — | — | |
| Lease liabilities (non-current) | 1.4—6.6% | 1.4+8.6%6.6% | 1.5+9.8%8.3% | 1.5+10.9%6.7% | 1.3−11.7%4.5% | 1.3−12.6%6.4% | 1.3−13.4%6.1% | 1.4−14.1%5.3% | 1.4−13.7%5.3% | 1.5—6.2% | 1.5—5.1% | 1.6—5.6% | 1.7—5.4% | |
| Total liabilities | 10—48.7% | 10−21.9%48.7% | 11−21.6%61.2% | 12−18.3%51.3% | 12−13.6%43.3% | 13−14.6%65.5% | 14−12.3%63.3% | 14−10.4%56.0% | 14−18.4%52.3% | 16—64.8% | 16—52.4% | 16—55.9% | 17—56.7% | |
| Retained earnings | −556—−2604% | −556—−2604% | −550—−3108% | −545—−2380% | −539—−1916% | −533—−2623% | −528—−2420% | −521—−2028% | −514—−1904% | −508—−2110% | −501—−1667% | −494—−1720% | −487—−1596% | |
| Shareholders' equity | 11—51.3% | 11+56.0%51.3% | 6.9−14.0%38.8% | 11−1.5%48.7% | 16+24.0%56.7% | 7.0−17.1%34.5% | 8.0−44.1%36.7% | 11−10.6%44.0% | 13−2.6%47.7% | 8.5—35.2% | 14—47.6% | 13—44.1% | 13—43.3% | |
| Total liabilities and equity | 21—100% | 21+5.0%100% | 18−18.8%100% | 23−10.9%100% | 28+4.3%100% | 20−15.5%100% | 22−27.4%100% | 26−10.5%100% | 27−11.6%100% | 24—100% | 30—100% | 29—100% | 31—100% | |
| Shares outstanding | 18—— | 18+231%— | 8.5−89.9%— | 8.4−88.6%— | 8.0+277%— | 5.3−90.2%— | 84+56.0%— | 74+48.1%— | 2.1r64−95.5%— | 54—— | 54—— | 50—— | 47—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 3.8−2.2%— | 0.9*−1.3%— | 1.0*−1.4%— | 1.0−3.1%— | 1.0*−3.1%— | 1.0*−2.6%— | 1.0*−1.9%— | 1.0−0.9%— | 1.0*−0.7%— | 1.0*—— | 1.0*—— | 1.0—— | 1.0*—— | |
| Share-based compensation | 1.8−18.5%— | 0.5*+518%— | 0.5*−34.2%— | 0.4−37.7%— | 0.4*−39.3%— | 0.1*−89.9%— | 0.7*−52.1%— | 0.7−48.6%— | 0.7*−44.6%— | 0.7*—— | 1.4*—— | 1.4—— | 1.3*—— | |
| Cash from operating activities | −17—— | −4.0*—— | −4.0*—— | −4.0—— | −4.7*—— | −3.9*—— | −4.4*—— | −4.1—— | −4.8r−4.8*—— | −4.6r−4.6*—— | −4.5*—— | −4.9—— | −5.0*—— | |
| Capital expenditure | −0.0—— | 0*—— | 0*—— | 0—— | −0.0*—— | 0*—— | 0*—— | −0.0—— | −0.0*—— | −0.0*—— | 0*—— | −0.1—— | 0*—— | |
| Intangible assets bought | — | — | — | — | 0*—— | 0*—— | — | — | 0*—— | 0*—— | 0*—— | −0.0—— | −0.0*—— | |
| Cash from investing activities | −0.0—— | 0*—— | 0*—— | 0—— | −0.0*—— | 0*—— | 0*—— | −0.0—— | −0.0*—— | −0.0*—— | 0*—— | −0.1—— | −0.0*—— | |
| Shares issued | 25+8.7%— | 9.7*+94.0%— | 0*−100%— | 0−100%— | 16*+45.1%— | 5.0*—— | 2.6*−67.0%— | 5.0+0.4%— | 11*+117%— | 0*—— | 7.8*—— | 5.0—— | 5.0*—— | |
| Cash from financing activities | 21+14.7%— | 8.7*+128%— | −0.4*−122%— | −0.7−116%— | 14*+50.6%— | 3.8*—— | 1.7*−74.5%— | 4.0+0.0%— | 9.2*+126%— | −0.3*—— | 6.6*—— | 4.0—— | 4.1*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at CEL-SCI Corporation#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Geert R. Kersten | $920 K | $618 K | $397 K | $9920 |
| 2024Geert R. Kersten | $1.1 M | $912 K | $468 K | $9650 |
| 2023Geert R. Kersten | $1.0 M | $660 K | $368 K | $11370 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at CEL-SCI Corporation#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 2 · Material agreement 10 · Shareholder rights changed 2 · Shareholder vote 3
| Filed | What happened | Filing |
|---|---|---|
| Shareholder vote | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K | |
| Shareholder rights changed | 8-K | |
| Shareholder rights changed | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Aug 17, 2026
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Feb 2017 | $1 M | Private placement after listing | Under $2 million | 2 | options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by CEL-SCI Corporation#
$190 K spent on lobbying the US Congress and federal agencies in 2020, most often on medical/disease research/clinical labs.
- Medical/Disease Research/Clinical Labs4 reports
Lobbying firms hired in 2020
The Petrizzo Group, Inc. $190 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2020 | $190 K | — | 4 |
| 2019 | $100 K | — | 3 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Cel-Sci Corporation”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
How CEL-SCI Corporation compares in Biotechnology
- Market cap$26 M · higher than 20% of 726
- Revenue growth62.5% · higher than 77% of 438
- Price / book1.6× · lower than 63% of 534
- FCF yield-65.0% · higher than 19% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| CEL-SCI Corporation🇺🇸 | $26 M | — | — | +62.5% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending September-2025
- Balance sheet:
- As of September-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, Wikipedia, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at CEL-SCI Corporation? Verify and update this profile — free
Show CEL-SCI Corporation's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.